ANSWER: Sun Pharma
Explanation:
This move will strengthen Sun’s branded ophthalmic portfolio in the US. The deal gives Sun Pharma access to four late stage branded ophthalmic products in the US. For the 6-month period ending June, InSite Vision recorded revenues of $3.8 million, an EBITDA loss of USD 6.4 million and a net loss of $7.5 million.